Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Cancer Treatment Reviews

Volumn 39, Issue 8, 2013, Pages 935-946

  Saini, Kamal S ^a,b   Loi, Sherene ^c   de Azambuja, Evandro ^b   Metzger Filho, Otto ^d   Saini, Monika Lamba ^e   Ignatiadis, Michail ^b   Dancey, Janet E ^f   Piccart Gebhart, Martine J ^a,b  

^a Breast International Group   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^f QUEEN S UNIVERSITY   (Canada)

Author keywords

Breast cancer; Cross talk; Dual inhibition; MAPK; MTOR; Personalized medicine; PI3K; Ras Raf MEK ERK; Targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO) N (2 HYDROXYETHOXY) 5 [(3 OXO 1,2 OXAZINAN 2 YL)METHYL]BENZAMIDE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; AFURESERTIB; APITOLISIB; ARRY 438162; ARRY 483162; AZD 5363; AZD 8055; AZD 8330; B RAF KINASE INHIBITOR; BAY 86 9766; BGT 226; BUPARLISIB; BYL 719; CC 223; COBIMETINIB; COPANLISIB; DABRAFENIB; EVEROLIMUS; EXEMESTANE; GDC 0032; GDC 0068; GSK 2126458; GSK 2141795; INK 1117; INK 128; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MLN 1117; MSC 1936369B; PF 04691502; PF 05212384; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PKI 587; PLACEBO; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAF PROTEIN; RAPAMYCIN; RDEA 119; RIDAFOROLIMUS; SELUMETINIB; SORAFENIB; TAK 733; TAMOXIFEN; TEMSIROLIMUS; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 147; XL 281; XL 765;

ACIDOSIS; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ARTERY THROMBOSIS; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CARCINOGENESIS; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DIARRHEA; DRUG TARGETING; DYSGEUSIA; DYSPNEA; ELECTROLYTE DISTURBANCE; FATIGUE; GENE EXPRESSION; GENE MUTATION; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; LACTIC ACIDOSIS; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHOMA; MACULOPAPULAR RASH; MOOD CHANGE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; VOMITING;

BREAST CANCER; CROSS-TALK; DUAL INHIBITION; MAPK; MTOR; PERSONALIZED MEDICINE; PI3K; RAS/RAF/MEK/ERK; TARGETED THERAPY;

BREAST NEOPLASMS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

EID: 84883556505     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.03.009     Document Type: Review

References (180)

1. Malvezzi M., Bertuccio P., Levi F., La Vecchia C., Negri E. European cancer mortality predictions for the year 2013. Ann Oncol 2013, 24(3):792-800.
2. Anderson W.F., Katki H.A., Rosenberg P.S. Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 2011, 103(18):1397-1402.
3. Polyak K., Metzger Filho O. SnapShot: breast cancer. Cancer Cell 2012, 22(4):562. e1.
4. Sugimoto Y., Whitman M., Cantley L.C., Erikson R.L. Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc Natl Acad Sci U S A 1984, 81(7):2117-2121.
5. Graupera M., Guillermet-Guibert J., Foukas L.C., Phng L.K., Cain R.J., Salpekar A., et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008, 453(7195):662-666.
6. Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S.H., et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454(7205):776-779.
7. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8(8):627-644.
8. Agoulnik I.U., Hodgson M.C., Bowden W.A., Ittmann M.M. INPP4B: the new kid on the PI3K block. Oncotarget 2011, 2(4):321-328.
9. Gonzalez-Angulo A.M., Blumenschein G.R. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 2013, 39(4):313-320.
10. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev 1999, 13(22):2905-2927.
11. Zhang Y.-J., Duan Y., Zheng X.F.S. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today 2011, 10.1016/j.drudis.2011.02.008.
12. Wan X., Harkavy B., Shen N., Grohar P., Helman L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26(13):1932-1940.
13. Brachmann S.M., Hofmann I., Schnell C., Fritsch C., Wee S., Lane H., et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 2009, 106(52):22299-22304.
14. Di Nicolantonio F., Arena S., Tabernero J., Grosso S., Molinari F., Macarulla T., et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010, 120(8):2858-2866.
15. Weigelt B., Warne P.H., Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011, 30(29):3222-3233.
16. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366(6):520-529.
17. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324(5930):1029-1033.
18. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304(5670):554.
19. Samuels Y., Diaz L.A., Schmidt-Kittler O., Cummins J.M., Delong L., Cheong I., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7(6):561-573.
20. Isakoff S.J., Engelman J.A., Irie H.Y., Luo J., Brachmann S.M., Pearline R.V., et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005, 65(23):10992-11000.
21. Loi S., Haibe-Kains B., Majjaj S., Lallemand F., Durbecq V., Larsimont D., et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 2010, 107(22):10208-10213.
22. Michelucci A., Di Cristofano C., Lami A., Collecchi P., Caligo A., Decarli N., et al. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol 2009, 18(4):200-205.
23. Comprehensive molecular portraits of human breast tumors. Nature 2012, 490(7418):61-70.
24. Serra V., Scaltriti M., Prudkin L., Eichhorn P.J., Ibrahim Y.H., Chandarlapaty S., et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011, 30(22):2547-2557.
25. Wallin J.J., Guan J., Edgar K.A., Zhou W., Francis R., Torres A.C., et al. Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes. PLoS One 2012, 7(5):e36402.
26. Stephens P.J., Tarpey P.S., Davies H., Van Loo P., Greenman C., Wedge D.C., et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486(7403):400-404.
27. Zhang S., Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010, 16(17):4325-4330.
28. Cully M., You H., Levine A.J., Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev 2006, 6(3):184-192.
29. Guenard F., Labrie Y., Ouellette G., Beauparlant C.J., Bessette P., Chiquette J., et al. Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families. Fam Cancer 2007, 6(4):483-490.
30. Tran L.M., Chang C.J., Plaisier S., Wu S., Dang J., Mischel P.S., et al. Determining PTEN functional status by network component deduced transcription factor activities. PLoS One 2012, 7(2):e31053.
31. Poliseno L., Salmena L., Zhang J., Carver B., Haveman W.J., Pandolfi P.P. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010, 465(7301):1033-1038.
32. Wee S., Wiederschain D., Maira S.M., Loo A., Miller C., DeBeaumont R., et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 2008, 105(35):13057-13062.
33. Yonemori K., Tsuta K., Shimizu C., Hatanaka Y., Hashizume K., Ono M., et al. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol (Northwood, London, England) 2009, 26(3):344-349.
34. Barbareschi M., Cuorvo L.V., Girlando S., Bragantini E., Eccher C., Leonardi E., et al. PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Virchows Arch 2012, 461(2):129-139.
35. Fleming G.F., Ma C.X., Huo D., Sattar H., Tretiakova M., Lin L., et al. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 2012, 224.
36. Slamon D.J., DeKernion J.B., Verma I.M., Cline M.J. Expression of cellular oncogenes in human malignancies. Science 1984, 224(4646):256-262.
37. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15(5):429-440.
38. She Q.B., Chandarlapaty S., Ye Q., Lobo J., Haskell K.M., Leander K.R., et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008, 3(8):e3065.
39. Tanaka H., Yoshida M., Tanimura H., Fujii T., Sakata K., Tachibana Y., et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 2011, 17(10):3272-3281.
40. Whyte D.B., Holbeck S.L. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun 2006, 340(2):469-475.
41. Miller T.W., Hennessy B.T., Gonzalez-Angulo A.M., Fox E.M., Mills G.B., Chen H., et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010, 120(7):2406-2413.
42. Hennessy B.T., Lu Y., Gonzalez-Angulo A.M., Carey M.S., Myhre S., Ju Z., et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteom 2010, 6(4):129-151.
43. + breast cancer. Breast Cancer Res 2010, 12(3):R40.
44. Zardavas D., Fumagalli D., Loi S. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?. Curr Opin Oncol 2012, 24(6):623-634.
45. Saal L.H., Gruvberger-Saal S.K., Persson C., Lovgren K., Jumppanen M., Staaf J., et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008, 40(1):102-107.
46. Boyault S., Drouet Y., Navarro C., Bachelot T., Lasset C., Treilleux I., et al. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat 2012, 132(1):29-39.
47. Marty B., Maire V., Gravier E., Rigaill G., Vincent-Salomon A., Kappler M., et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008, 10(6):R101.
48. Gonzalez-Angulo A.M., Ferrer-Lozano J., Stemke-Hale K., Sahin A., Liu S., Barrera J.A., et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 2011, 10(6):1093-1101.
49. Santen R.J., Song R.X., McPherson R., Kumar R., Adam L., Jeng M.H., et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002, 80(2):239-256.
50. Poulikakos P.I., Solit D.B. Resistance to MEK inhibitors: should we co-target upstream?. Sci Signal 2011, 4(166):pe16.
51. Srinivasan R., Zabuawala T., Huang H., Zhang J., Gulati P., Fernandez S., et al. Erk1 and Erk2 regulate endothelial cell proliferation and migration during mouse embryonic angiogenesis. PLoS One 2009, 4(12):e8283.
52. Galabova-Kovacs G., Kolbus A., Matzen D., Meissl K., Piazzolla D., Rubiolo C., et al. ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts. Cell Cycle (Georgetown, Tex) 2006, 5(14):1514-1518.
53. Giroux S., Tremblay M., Bernard D., Cardin-Girard J.F., Aubry S., Larouche L., et al. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol 1999, 9(7):369-372.
54. Rebbeck T.R., DeMichele A., Tran T.V., Panossian S., Bunin G.R., Troxel A.B., et al. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis 2009, 30(2):269-274.
55. Santarpia L., Qi Y., Stemke-Hale K., Wang B., Young E.J., Booser D.J., et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 2012, 134(1):333-343.
56. Mittal S., Subramanyam D., Dey D., Kumar R.V., Rangarajan A. Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Mol Cancer 2009, 8:128.
57. Young A., Lou D., McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov 2013, 3(1):112-123.
58. Ellis M.J., Ding L., Shen D., Luo J., Suman V.J., Wallis J.W., et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012, 486(7403):353-360.
59. Mirzoeva O.K., Das D., Heiser L.M., Bhattacharya S., Siwak D., Gendelman R., et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009, 69(2):565-572.
60. Hoeflich K.P., O'Brien C., Boyd Z., Cavet G., Guerrero S., Jung K., et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009, 15(14):4649-4664.
61. Creighton C.J., Hilger A.M., Murthy S., Rae J.M., Chinnaiyan A.M., El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006, 66(7):3903-3911.
62. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441(7092):424-430.
63. Janku F., Lee J.J., Tsimberidou A.M., Hong D.S., Naing A., Falchook G.S., et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 2011, 6(7):e22769.
64. Sos M.L., Fischer S., Ullrich R., Peifer M., Heuckmann J.M., Koker M., et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A 2009, 106(43):18351-18356.
65. Garon E.B., Finn R.S., Hosmer W., Dering J., Ginther C., Adhami S., et al. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther 2010, 9(7):1985-1994.
66. Dry J.R., Pavey S., Pratilas C.A., Harbron C., Runswick S., Hodgson D., et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 2010, 70(6):2264-2273.
67. Chang F., Lee J.T., Navolanic P.M., Steelman L.S., Shelton J.G., Blalock W.L., et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003, 17(3):590-603.
68. Carracedo A., Pandolfi P.P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008, 27(41):5527-5541.
69. Balmanno K., Chell S.D., Gillings A.S., Hayat S., Cook S.J. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 2009, 125(10):2332-2341.
70. Meng J., Peng H., Dai B., Guo W., Wang L., Ji L., et al. High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther 2009, 8(21):2073-2080.
71. Hausenloy D.J., Mocanu M.M., Yellon D.M. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res 2004, 63(2):305-312.
72. Grant S. Cotargeting survival signaling pathways in cancer. J Clin Invest 2008, 118(9):3003-3006.
73. She Q.B., Solit D.B., Ye Q., O'Reilly K.E., Lobo J., Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumour cells. Cancer Cell 2005, 8(4):287-297.
74. Wang J., Yuan Y., Zhou Y., Guo L., Zhang L., Kuai X., et al. Protein interaction data set highlighted with human Ras-MAPK/PI3K signaling pathways. J Proteome Res 2008, 7(9):3879-3889.
75. Zimmermann S., Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science (New York, NY) 1999, 286(5445):1741-1744.
76. Karbowniczek M., Robertson G.P., Henske E.P. Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. J Biol Chem 2006, 281(35):25447-25456.
77. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121(2):179-193.
78. Roux P.P., Ballif B.A., Anjum R., Gygi S.P., Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Nat Acad Sci U S A 2004, 101(37):13489-13494.
79. Vasudevan K.M., Burikhanov R., Goswami A., Rangnekar V.M. Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Res 2007, 67(21):10343-10350.
80. She Q.B., Halilovic E., Ye Q., Zhen W., Shirasawa S., Sasazuki T., et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010, 18(1):39-51.
81. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118(9):3065-3074.
82. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19(1):58-71.
83. Bachelot T, Bourgier C, Cropet C, Guastalla J-P, Ferrero J-M, Leger-Falandry C, et al. A GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Proc. of the San Antonio breast cancer symposium. 2010 [Abstract S1-6].
84. Huynh H. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. Cancer 2010, 116(5):1315-1325.
85. Chang Q., Chen E., Hedley D.W. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. Cancer Biol Ther 2009, 8(20):1893-1901.
86. Chapuis N., Tamburini J., Green A.S., Vignon C., Bardet V., Neyret A., et al. Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 2010, 16(22):5424-5435.
87. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14(12):1351-1356.
88. Klaus Hoeflich M.M., Den Otter Doug, Chan Jocelyn, Chan Emily, Orr Christine, Friedman Lori, et al. Preclinical combination efficacy and identification of biomarkers of MEK and PI3K inhibitors in phase I. Mol Cancer Ther 2009, 8(12, Suppl.1). Abstract A250.
89. Sparks C.A., Guertin D.A. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010, 29(26):3733-3744.
90. Yu K., Toral-Barza L., Discafani C., Zhang W.G., Skotnicki J., Frost P., et al. MTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001, 8(3):249-258.
91. Chan S., Scheulen M.E., Johnston S., Mross K., Cardoso F., Dittrich C., et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005, 23(23):5314-5322.
92. Wolff A.C., Lazar A.A., Bondarenko I., Garin A.M., Brincat S., Chow L., et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013, 31(2):195-202.
93. Pal I., Mandal M. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin 2012, 33(12):1441-1458.
94. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28(6):1075-1083.
95. Ghayad S.E., Cohen P.A. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anti-Cancer Drug Discov 2009, 5(1):29-57.
96. Vilar E., Perez-Garcia J., Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011, 10(3):395-403.
97. Friday B.B., Adjei A.A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008, 14(2):342-346.
98. Malaguti P., Vari S., Cognetti F., Fabi A. The mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions. Anticancer Res 2013, 33(1):21-28.
99. Rinehart J., Adjei A.A., Lorusso P.M., Waterhouse D., Hecht J.R., Natale R.B., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004, 22(22):4456-4462.
100. Bianchi G., Loibl S., Zamagni C., Salvagni S., Raab G., Siena S., et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009, 20(7):616-624.
101. Moreno-Aspitia A., Morton R.F., Hillman D.W., Lingle W.L., Rowland K.M., Wiesenfeld M., et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009, 27(1):11-15.
102. Yeh T.C., Marsh V., Bernat B.A., Ballard J., Colwell H., Evans R.J., et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007, 13(5):1576-1583.
103. Chappell W.H., Steelman L.S., Long J.M., Kempf R.C., Abrams S.L., Franklin R.A., et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011, 2(3):135-164.
104. Jokinen E., Laurila N., Koivunen J.P. Alternative dosing of dual PI3K and MEK inhibition in cancer therapy. BMC Cancer 2012, 12(1):612.
105. Tolcher A.W., Baird R.D., Patnaik A., Moreno Garcia V., Papadopoulos K.P., Garrett C.R., et al. A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol 2011, 29. (suppl; abstr 3004).
106. Shapiro G., LoRusso P., Kwak E.L., Cleary J.M., Musib L., Jones C., et al. Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. J Clin Oncol 2011, 29. (suppl; abstr 3005).
107. Di Cosimo S., Bendell J.C., Cervantes-Ruiperez A., Roda D., Prudkin L., Stein M.N., et al. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol 2010, 28:15s. (suppl; abstr 3008).
108. Weigelt B., Downward J. Genomic determinants of PI3K pathway inhibitor response in cancer. Front Oncol 2012, 2:109.
109. Burris H.A. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 2013, 1.
110. Shimizu T., Tolcher A.W., Papadopoulos K.P., Beeram M., Rasco D.W., Smith L.S., et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase I study: The START Center experience. J Clin Oncol 2011, 29.
111. Janku F., Wheler J.J., Westin S.N., Moulder S.L., Naing A., Tsimberidou A.M., et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012, 30(8):777-782.
112. Janku F., Wheler J.J., Naing A., Falchook G.S., Hong D.S., Stepanek V.M., et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 2013, 73(1):276-284.
113. Duncan J.S., Whittle M.C., Nakamura K., Abell A.N., Midland A.A., Zawistowski J.S., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149(2):307-321.
114. Ihle N.T., Paine-Murrieta G., Berggren M.I., Baker A., Tate W.R., Wipf P., et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005, 4(9):1349-1357.
115. Grana B., Burris H.A., Rodon Ahnert J., Abdul Razak A.R., De Jonge M.J., Eskens F., et al. Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy. J Clin Oncol 2011, 29. (suppl; abstr 3043).
116. Tolcher A.W., Yap T.A., Fearen I., Taylor A., Carpenter C., Brunetto A.T., et al. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J Clin Oncol 2009, 27:15s. (suppl; abstr 3503).
117. LoRusso P., Markman B., Tabernero J., Shazer R., Nguyen L., Heath E., et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. J Clin Oncol 2009, 27:15s. (suppl; abstr 3502).
118. Jimeno A., Herbst R.S., Falchook G.S., Messersmith W.A., Hecker S., Peterson S., et al. Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. J Clin Oncol 2010, 28:15. (suppl; abstr 3089).
119. Munster P.N., van der Noll R., Voest E.E., Dees E.C., Tan A.R., Specht J.M., et al. Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). J Clin Oncol 2011, 29. (suppl; abstr 3018).
120. Burris H.A., Siu L.L., Infante J.R., Wheler J.J., Kurkjian C., Opalinska J., et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. J Clin Oncol 2011, 29. (suppl; abstr 3003).
121. Ellard S.L., Clemons M., Gelmon K.A., Norris B., Kennecke H., Chia S., et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009, 27(27):4536-4541.
122. Sanchez-Fructuoso A.I., Ruiz J.C., Perez-Flores I., Gomez Alamillo C., Calvo Romero N., Arias M. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Transpl Proc 2010, 42(8):3050-3052.
123. Bendell J.C., Rodon J., Burris H.A., de Jonge M., Verweij J., Birle D., et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012, 30(3):282-290.
124. Parithivel K., Ramaiya N., Jagannathan J.P., O'Regan K., Krajewski K., Fisher D., et al. Everolimus- and temsirolimus-associated enteritis: report of three cases. J Clin Oncol 2011, 29(14):e404-e406.
125. Morrow P.K., Wulf G.M., Ensor J., Booser D.J., Moore J.A., Flores P.R., et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011, 29(23):3126-3132.
126. Clermont A.C., Cahill M., Salti H., Rook S.L., Rask-Madsen C., Goddard L., et al. Hepatocyte growth factor induces retinal vascular permeability via MAP-kinase and PI-3 kinase without altering retinal hemodynamics. Invest Ophthalmol Vis Sci 2006, 47(6):2701-2708.
127. Delord J., Houede N., Awada A., Taamma A., Faivre S.J., Besse-Hammer T., et al. First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors. J Clin Oncol 2010, 28:15s. (abstr 2504).
128. Adjei A.A., Cohen R.B., Franklin W., Morris C., Wilson D., Molina J.R., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008, 26(13):2139-2146.
129. Leijen S., Middleton M.R., Tresca P., Kraeber-Bodere F., Dieras V., Scheulen M.E., et al. Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced/metastatic solid tumor. J Clin Oncol 2011, 29. (suppl; abstr 3017).
130. Houede N., Faivre S.J., Awada A., Raymond E., Italiano A., Besse-Hammer T., et al. Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies. J Clin Oncol 2011, 29. (suppl; abstr 3019).
131. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res 2008, 68(9):3077-3080. discussion 80.
132. Dancey J.E., Chen H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006, 5(8):649-659.
133. DeVita V.T. The most important news at ASCO 2009. Nat Rev Clin Oncol 2009, 6(7):371.
134. Quinlan J., Gaydos B., Maca J., Krams M. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clin Trial (London, England) 2010, 7(2):167-173.
135. Pearson S.A., Chin M., Faedo M., Ward R. Rationale for treatment durations of targeted cancer agents. Lancet Oncol 2010, 11(12):1113-1115.
136. Glimelius B., Lahn M. Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Ann Oncol 2011, 2(8):1717-1725.
137. Barker A.D., Sigman C.C., Kelloff G.J., Hylton N.M., Berry D.A., Esserman L.J. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009, 86(1):97-100.
138. Kalinsky K., Sparano J.A., Kim M., Crew K.D., Maurer M.A., Taback B., et al. Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer. J Clin Oncol 2011, 29:22. (suppl; abstr TPS147).
139. Moreno-Aspitia A. Neoadjuvant therapy in early-stage breast cancer. Crit Rev Oncol Hematol 2012, 2(2):187-199.
140. McDermott U., Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol 2009, 27(33):5650-5659.
141. Saal L.H., Johansson P., Holm K., Gruvberger-Saal S.K., She Q.B., Maurer M., et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007, 104(18):7564-7569.
142. Creighton C.J. A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene 2007, 26(32):4648-4655.
143. Sawyers C.L. The cancer biomarker problem. Nature 2008, 452(7187):548-552.
144. Blay J.Y., Lacombe D., Meunier F., Stupp R. Personalised medicine in oncology: questions for the next 20 years. Lancet Oncol 2012, 13(5):448-449.
145. Weigelt B., Pusztai L., Ashworth A., Reis-Filho J.S. Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol 2011, 9(1):58-64.
146. Azim H.A., Michiels S., Zagouri F., Delaloge S., Filipits M., Namer M., et al. Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol 2013, 24(3):647-654.
147. Hassett M.J., Silver S.M., Hughes M.E., Blayney D.W., Edge S.B., Herman J.G., et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 2012, 30(18):2218-2226.
148. Gonzalez-Angulo A.M., Hennessy B.T., Mills G.B. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 2010, 28(16):2777-2783.
149. Tian Q., Price N.D., Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Int Med 2012, 271(2):111-121.
150. Dijkers E.C., Oude Munnink T.H., Kosterink J.G., Brouwers A.H., Jager P.L., de Jong J.R., et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010, 87(5):586-592.
151. Yap T.A., Yan L., Patnaik A., Olmos D., Fearen I., Baird R.D., et al. Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers. J Clin Oncol 2011, 29. (suppl; abstr 3001).
152. Gore L., Trippett T.M., Katzenstein H.M., Boklan J.L., Narendaren A., Smith A., et al. J Clin Oncol 2010, 28:15s. (suppl; abstr 9531).
153. Tabernero J., Cervantes A., Gordon M.S., Chiorean E.G., Burris H.A. A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies. Cancer Res. 2012, 72(8):CT-02.
154. Tan D.S., Dumez H., Olmos D., Sandhu S.K., Hoeben A., Stephens A.W., et al. First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. J Clin Oncol 2010, 28:15s. (suppl; abstr 3006).
155. Naing A., Aghajanian C., Raymond E., Kurzrock R., Blanco M., Oelmann E., et al. First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor. Mol Cancer Ther 2011, 10:A168. (Meeting Abstract Supplement).
156. Shih K.C., Bendell J.C., Reinert A., Jones S., Kelley R.K., Infante J.R., et al. Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers. J Clin Oncol 2012, 30. (suppl; abstr 3006).
157. Shapiro G., Kwak E., Baselga J., Rodon J., Scheffold C., Laird A.D., et al. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J Clin Oncol 2009, 27:15s. (suppl; abstr 3500).
158. Moreno Garcia V., Baird R.D., Shah K.J., Basu B., Tunariu N., Blanco M., et al. A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. J Clin Oncol 2011, 29. (suppl; abstr 3021).
159. Patnaik A., Appleman L.J., Mountz J.M., Ramanathan R.K., Beeram M., Tolcher A.W., et al. A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: results of dose-escalation phase. J Clin Oncol 2011, 29. (suppl; abstr 3035).
160. Jimeno A., Herbst R.S., Falchook G.S., Messersmith W.A., Hecker S., Peterson S., et al. Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. J Clin Oncol 2010, 28:15s. (suppl; abstr 3089).
161. Chiorean E.G., Mahadevan D., Harris W.B., Von Hoff D.D., Younger A.E., Rensvold D.M., et al. Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J Clin Oncol 2009, 27:15s. (suppl; abstr 2558).
162. Juric D., Rodon J., Gonzalez-Angulo A.M., Burris H.A., Bendell J., Berlin J.D., et al. BYL719, a next generation PI3K alpha specific inhibitor: preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Res 2012, 72(Suppl. 8):CT-01.
163. Burris H., Rodon J., Sharma S., Herbst R.S., Tabernero J., Infante J.R., et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol 2010, 28:15s. (suppl; abstr 3005).
164. Peyton J.D., Ahnert J.R., Burris H., Britten C., Chen L.C., Tabernero J., et al. A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. J Clin Oncol 2011, 29.
165. Brana I., LoRusso P., Baselga J., Heath E.I., Patnaik A., Gendreau S., et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010, 28:15s. (suppl; abstr 3030).
166. Munster P., van der Noll R., Voest E., Specht J., Werner T.L., Dees E.C., et al. PI3K kinase inhibitor GSK2126458 (GSK458): clinical activity in select patient populations defined by predictive markers (study P3K112826). Ann Oncol 2012, 23(Suppl. 9):ix152-ix174. (Abstract 4420).
167. Canon J.L., Bergh J., Saura C., Oliveira M., Houk B., Millham R., et al. Phase Ib/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen Receptor-positive, HER2-negative early breast cancer (BC): phase Ib preliminary data. Cancer Res 2012, 72(Suppl. 24). OT2-3-02.
168. Wagner A.J., Bendell J.C., Dolly S., Morgan J.A., Ware J.A., Fredrickson J., et al. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J Clin Oncol 2011, 29. (suppl; abstr 3020).
169. Millham R., Houk B., Borzillo G., Tabernero J., Bell-McGuinn K., Bendell J., et al. First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: update on safety, efficacy, and pharmacology. Mol Cancer Ther 2011, 10:A167. (Meeting Abstract Supplement).
170. Tolcher A.W., Yap T.A., Fearen I., Taylor A., Carpenter C., Brunetto A.T., et al. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J Clin Oncol 2009, 27:15s. (suppl; abstr 3503).
171. Burris H.A., Siu L.L., Infante J.R., Wheler J.J., Kurkjian C., Opalinska J., et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. J Clin Oncol 2011, 29. (suppl; abstr 3003).
172. Schwartz G.K., Robertson S., Shen A., Wang E., Pace L., Dials H., et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. J Clin Oncol 2009, 27:15s. (suppl; abstr 3513).
173. Kefford R., Arkenau H., Brown M.P., Millward M., Infante J.R., Long G.V., et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010, 28:15s. (suppl; abstr 8503).
174. Thompson D.S., Flaherty K., Messersmith W., Harlacker K., Nallapareddy S., Vincent C., et al. A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma. J Clin Oncol 2009, 27. (suppl; abstr e14584).
175. Leijen S., Middleton M.R., Tresca P., Kraeber-Bodere F., Dieras V., Scheulen M.E., et al. Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced/metastatic solid tumor. J Clin Oncol 2011, 29. (suppl; abstr 3017).
176. Gore L., Lewis K., Von Hoff D.D., Weiss G.J., Ramanathan R.K., Adjei A.A., et al. Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer. J Clin Oncol 2011, 29. (suppl; abstr 3007).
177. Sosman J.A., Adjei A.A., LoRusso P., Michael S.A., Dy G.K., Bowditch A., et al. First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma. J Clin Oncol 2011, 29. (suppl; abstr TPS145).
178. Rosen L.S., Galatin P., Fehling J.M., Laux I., Dinolfo M., Frye J., et al. A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors. J Clin Oncol 2008, 26. (May 20 suppl; abstr 14585).
179. Houede N., Faivre S.J., Awada A., Raymond E., Italiano A., Besse-Hammer T., et al. Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies. J Clin Oncol 2011, 29. (suppl; abstr 3019).
180. Bendell J.C., Papadopoulos K., Jones S.F., Barrett E., Guthrie K., Kass C.L., et al. A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors. Mol Cancer Ther 2011, 10:B243. (Meeting Abstract Supplement).